AU2001279090A1 - Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases - Google Patents

Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases

Info

Publication number
AU2001279090A1
AU2001279090A1 AU2001279090A AU7909001A AU2001279090A1 AU 2001279090 A1 AU2001279090 A1 AU 2001279090A1 AU 2001279090 A AU2001279090 A AU 2001279090A AU 7909001 A AU7909001 A AU 7909001A AU 2001279090 A1 AU2001279090 A1 AU 2001279090A1
Authority
AU
Australia
Prior art keywords
fluorenes
hydroxyimino
heterocyclic
protein kinases
inhibiting protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001279090A
Other languages
English (en)
Inventor
Wesley Kwan Mung Chong
Rohit Kumar Duvadie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agouron Pharmaceuticals LLC
Original Assignee
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals LLC filed Critical Agouron Pharmaceuticals LLC
Publication of AU2001279090A1 publication Critical patent/AU2001279090A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2001279090A 2000-08-18 2001-07-31 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases Abandoned AU2001279090A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22480500P 2000-08-18 2000-08-18
US60224805 2000-08-18
PCT/US2001/023897 WO2002016326A1 (en) 2000-08-18 2001-07-31 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases

Publications (1)

Publication Number Publication Date
AU2001279090A1 true AU2001279090A1 (en) 2002-03-04

Family

ID=22842288

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001279090A Abandoned AU2001279090A1 (en) 2000-08-18 2001-07-31 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases

Country Status (16)

Country Link
US (1) US6462060B2 (ja)
EP (1) EP1309563B1 (ja)
JP (1) JP2004506720A (ja)
AR (1) AR032891A1 (ja)
AT (1) ATE295354T1 (ja)
AU (1) AU2001279090A1 (ja)
BR (1) BR0113258A (ja)
CA (1) CA2411924A1 (ja)
DE (1) DE60110802T2 (ja)
ES (1) ES2238463T3 (ja)
GT (1) GT200100170A (ja)
MX (1) MXPA03001452A (ja)
PA (1) PA8525701A1 (ja)
PE (1) PE20020289A1 (ja)
SV (1) SV2003000603A (ja)
WO (1) WO2002016326A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
WO2003061566A2 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
PT1680140E (pt) * 2003-10-16 2011-05-31 Imclone Llc Inibidores do receptor-1 do factor de crescimento de fibroblastos e m?todos de tratamento destes
CA2583315A1 (en) * 2004-10-06 2006-06-01 Tiltan Pharma Ltd. Method and composition for enhancing anti-angiogenic therapy
AR056645A1 (es) 2005-03-29 2007-10-17 Icos Corp Compuestos de urea sustituida inhibidores de enzimas chk1 .
WO2007026720A1 (ja) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. 縮環ピラゾール誘導体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
WO1996014843A2 (en) 1994-11-10 1996-05-23 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
EP0888310B1 (en) 1996-03-15 2005-09-07 AstraZeneca AB Cinnoline derivatives and use as medicine
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
WO1997045397A1 (en) * 1996-05-30 1997-12-04 Hoechst Marion Roussel, Inc. Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
ATE391719T1 (de) 1997-02-05 2008-04-15 Warner Lambert Co Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation
AU744986B2 (en) 1997-07-12 2002-03-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
PT1023063E (pt) 1997-10-06 2004-02-27 Abbott Gmbh & Co Kg Derivados de indeno¬1,2-c|- nafto¬1,2-c|- e benzo¬6,7|ciclo-hepta¬1,2-c|pirazole
ATE332896T1 (de) 1997-10-27 2006-08-15 Agouron Pharma 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin- abhängiger kinasen
DE69837282T2 (de) 1997-12-13 2007-11-08 Bristol-Myers Squibb Co. VERWENDUNG VON PYRAZOLO Ä 3,4-bÜ PYRIDIN ALS CYCLIN-ABHÄNGIGE KINASE HEMMER
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
HUP0100931A3 (en) 1998-02-26 2002-08-28 Aventis Pharma Inc 6,9-disubstituted 2-[trans-(-aminocyclohexyl)amino]purines and pharmaceutical compositions containing them
ATE432923T1 (de) 1998-04-21 2009-06-15 Bristol Myers Squibb Pharma Co 5-aminoindenoä1,2-cüpyrazol-4-one als antitumor- und wachstumshemmende mittel
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
ES2270612T3 (es) 1998-08-29 2007-04-01 Astrazeneca Ab Compuestos de pirimidina.
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
EP1109823B1 (en) * 1998-09-08 2005-11-16 Agouron Pharmaceuticals, Inc. Modifications of the vegf receptor-2 protein and methods of use
CN1335836A (zh) * 1998-11-06 2002-02-13 巴斯福股份公司 三环吡唑衍生物

Also Published As

Publication number Publication date
DE60110802T2 (de) 2005-10-06
PE20020289A1 (es) 2002-05-27
AR032891A1 (es) 2003-12-03
SV2003000603A (es) 2003-01-13
ES2238463T3 (es) 2005-09-01
EP1309563B1 (en) 2005-05-11
EP1309563A1 (en) 2003-05-14
BR0113258A (pt) 2003-07-15
JP2004506720A (ja) 2004-03-04
ATE295354T1 (de) 2005-05-15
US6462060B2 (en) 2002-10-08
CA2411924A1 (en) 2002-02-28
WO2002016326A1 (en) 2002-02-28
DE60110802D1 (de) 2005-06-16
MXPA03001452A (es) 2004-05-04
US20020049238A1 (en) 2002-04-25
PA8525701A1 (es) 2002-04-25
GT200100170A (es) 2002-05-16

Similar Documents

Publication Publication Date Title
IL146094A0 (en) Diaminothiazoles and their use for inhibiting protein kinases
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU2728201A (en) 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
AU2002213485A1 (en) Inhibitors of protein kinases
AU5173400A (en) Protein kinases
AU2001237041A1 (en) Kinase inhibitors
AU2001288249A1 (en) Biosensors and methods for their use
AU2001265008A1 (en) Caspase inhibitors and uses thereof
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU2001247882A1 (en) Tricyclic protein kinase inhibitors
AU2001268525A1 (en) Human kinases
AU2001238488A1 (en) Human kinases
AU2001288612A1 (en) Human kinases
AU2001277959A1 (en) Human kinases
AU2576501A (en) Protein kinase inhibitors
AU2001243394A1 (en) Compounds and methods
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2001286721A1 (en) Human interleukin-four induced protein
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AUPQ872300A0 (en) Compounds and methods
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
AU4686299A (en) Nek-related and bub1-related protein kinases
AU2001279090A1 (en) Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases
AU2591299A (en) Human protein kinase c inhibitor